{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:09:26Z","timestamp":1792069766683,"version":"4.4.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["-"],"award-info":[{"award-number":["-"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["-"],"award-info":[{"award-number":["-"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004091","name":"Kumamoto University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004091","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>Medication-Related Osteonecrosis of the Jaw (MRONJ) is a condition marked by osteonecrosis of the jaw bone and other symptoms seen following invasive surgical procedures in patients administered bone-modifying agents. Once disease develops, a patient\u2019s ADL levels are significantly compromised. However, the pathogenesis of this disease is not clearly understood.<\/jats:p>\n            <jats:p>Bisphosphonates (BPs) are bone resorption inhibitors commonly used to treat osteoporosis. Although not confirmed, it is generally believed that MRONJ risk is higher in the presence of injectable rather than oral formulations. Here, we assessed risk of developing ONJ in mice in the presence of 3 different BPs\u2014zoledronate, ibandronate, or alendronate\u2014that are administered clinically intravenously or via infusion.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and Methods<\/jats:title>\n            <jats:p>Eight-week-old wild-type mice were administered zoledronate, alendronate, ibandronate or PBS vehicle subcutaneously once a week for 2\u00a0weeks. Then the right first molars in the mandible were extracted. Six-weeks later, osteonecrosis development was analyzed by histochemistry.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Among mice administered BPs, mice treated with zoledronate exhibited the highest frequency of osteocytes exhibiting osteonecrosis. Bone mineral density was higher in mice receiving zoledronate, alendronate, or ibandronate than in PBS control mice, but effects of the 3 drugs were comparable. Moreover, formation of multi-nuclear osteoclasts in vitro was most strongly inhibited by zoledronate, followed by alendronate and ibandronate.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Administration of BPs with high osteoclastogenesis inhibitory potential, such as zoledronate, increases risk of ONJ development after tooth extraction more than treatment with other agents tested, even at equivalent dosage.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00774-025-01608-9","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:12:04Z","timestamp":1748391124000},"page":"370-383","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Bisphosphonates with high bone-resorption-capacity promote osteonecrosis of the jaw development after tooth extraction in mice"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6046-9677","authenticated-orcid":false,"given":"Ryuta","family":"Kubo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Tajiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hibiki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"key":"1608_CR1","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","volume":"80","author":"SL Ruggiero","year":"2022","unstructured":"Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D (2022) American Association of Oral and Maxillofacial Surgeons\u2019 Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update (in Eng). J Oral Maxillofac Surg 80:920\u2013943. https:\/\/doi.org\/10.1016\/j.joms.2022.02.008","journal-title":"J Oral Maxillofac Surg"},{"key":"1608_CR2","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/s0278-2391(03)00720-1","volume":"61","author":"RE Marx","year":"2003","unstructured":"Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115\u20131117. https:\/\/doi.org\/10.1016\/s0278-2391(03)00720-1","journal-title":"J Oral Maxillofac Surg"},{"key":"1608_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012432.pub3","author":"NH Beth-Tasdogan","year":"2022","unstructured":"Beth-Tasdogan NH, Mayer B, Hussein H, Zolk O, Peter JU (2022) Interventions for managing medication-related osteonecrosis of the jaw (in Eng). Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD012432.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"1608_CR4","doi-asserted-by":"publisher","unstructured":"Disel U, Besen AA, \u00d6zyi\u0307lkan \u00d6, Er E, Canpolat T (2012) A case report of bevacizumab-related osteonecrosis of the jaw: old problem, new culprit. Oral Oncol https:\/\/doi.org\/10.1016\/j.oraloncology.2011.07.030","DOI":"10.1016\/j.oraloncology.2011.07.030"},{"key":"1608_CR5","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1200\/jco.2008.19.2146","volume":"27","author":"K Fizazi","year":"2009","unstructured":"Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, Gao G, Wu L, Sohn W, Jun S (2009) Randomized Phase II Trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates (in Eng). J Clin Oncol 27:1564\u20131571. https:\/\/doi.org\/10.1200\/jco.2008.19.2146","journal-title":"J Clin Oncol"},{"key":"1608_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta17290","volume":"17","author":"J Ford","year":"2013","unstructured":"Ford J, Cummins E, Sharma P, Elders A, Stewart F, Johnston R, Royle P, Jones R, Mulatero C, Todd R, Mowatt G (2013) Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours (in Eng). Health Technol Assess 17:1\u2013386. https:\/\/doi.org\/10.3310\/hta17290","journal-title":"Health Technol Assess"},{"key":"1608_CR7","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","volume":"19","author":"RG Russell","year":"2008","unstructured":"Russell RG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy (in Eng). Osteoporos Int (Osteoporos Int) 19:733\u2013759. https:\/\/doi.org\/10.1007\/s00198-007-0540-8","journal-title":"Osteoporos Int (Osteoporos Int)"},{"key":"1608_CR8","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1159\/000151371","volume":"189","author":"MR Allen","year":"2009","unstructured":"Allen MR (2009) Bisphosphonates and osteonecrosis of the jaw: moving from the bedside to the bench (in Eng). Cells Tissues Organs 189:289\u2013294. https:\/\/doi.org\/10.1159\/000151371","journal-title":"Cells Tissues Organs"},{"key":"1608_CR9","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","volume":"48","author":"R Baron","year":"2011","unstructured":"Baron R, Ferrari S, Russell RGG (2011) Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 48:677\u2013692. https:\/\/doi.org\/10.1016\/j.bone.2010.11.020","journal-title":"Bone"},{"key":"1608_CR10","doi-asserted-by":"publisher","first-page":"8071579","DOI":"10.1155\/2018\/8071579","volume":"2018","author":"K Pimolbutr","year":"2018","unstructured":"Pimolbutr K, Porter S, Fedele S (2018) Osteonecrosis of the jaw associated with antiangiogenics in antiresorptive-na\u00efve patient: a comprehensive review of the literature. Biomed Res Int 2018:8071579. https:\/\/doi.org\/10.1155\/2018\/8071579","journal-title":"Biomed Res Int"},{"key":"1608_CR11","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s00520-018-4501-x","volume":"27","author":"O Nicolatou-Galitis","year":"2019","unstructured":"Nicolatou-Galitis O, Kouri M, Papadopoulou E, Vardas E, Galiti D, Epstein JB, Elad S, Campisi G, Tsoukalas N, Bektas-Kayhan K, Tan W, Body J-J, Migliorati C, Lalla RV, for the MBSG (2019) Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review. Support Care Cancer 27:383\u2013394. https:\/\/doi.org\/10.1007\/s00520-018-4501-x","journal-title":"Support Care Cancer"},{"key":"1608_CR12","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.jcms.2017.05.028","volume":"45","author":"S Aljohani","year":"2017","unstructured":"Aljohani S, Fliefel R, Ihbe J, K\u00fchnisch J, Ehrenfeld M, Otto S (2017) What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: a systematic review. J Cranio-Maxillofac Surg 45:1493\u20131502. https:\/\/doi.org\/10.1016\/j.jcms.2017.05.028","journal-title":"J Cranio-Maxillofac Surg"},{"key":"1608_CR13","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1177\/0022034514560768","volume":"94","author":"A Peer","year":"2015","unstructured":"Peer A, Khamaisi M (2015) Diabetes as a risk factor for medication-related osteonecrosis of the jaw. J Dent Res 94:252\u2013260. https:\/\/doi.org\/10.1177\/0022034514560768","journal-title":"J Dent Res"},{"key":"1608_CR14","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.3390\/jcm11092377","volume":"11","author":"S-M Park","year":"2022","unstructured":"Park S-M, Lee J-H (2022) Effects of Type 2 Diabetes mellitus on osteoclast differentiation, activity, and cortical bone formation in POSTmenopausal MRONJ patients. J Clin Med 11:2377","journal-title":"J Clin Med"},{"key":"1608_CR15","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s11914-010-0008-1","volume":"8","author":"SK Kumar","year":"2010","unstructured":"Kumar SK, Gorur A, Schaudinn C, Shuler CF, Costerton JW, Sedghizadeh PP (2010) The role of microbial biofilms in osteonecrosis of the jaw associated with bisphosphonate therapy (in Eng). Curr Osteoporos Rep 8:40\u201348. https:\/\/doi.org\/10.1007\/s11914-010-0008-1","journal-title":"Curr Osteoporos Rep"},{"key":"1608_CR16","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3390\/medicina57050463","volume":"57","author":"S Otto","year":"2021","unstructured":"Otto S, Aljohani S, Fliefel R, Ecke S, Ristow O, Burian E, Troeltzsch M, Pautke C, Ehrenfeld M (2021) Infection as an important factor in medication-related osteonecrosis of the jaw (MRONJ). Medicina 57:463","journal-title":"Medicina"},{"key":"1608_CR17","doi-asserted-by":"publisher","first-page":"46322","DOI":"10.1038\/srep46322","volume":"7","author":"M Morita","year":"2017","unstructured":"Morita M, Iwasaki R, Sato Y, Kobayashi T, Watanabe R, Oike T, Nakamura S, Keneko Y, Miyamoto K, Ishihara K, Iwakura Y, Ishii K, Matsumoto M, Nakamura M, Kawana H, Nakagawa T, Miyamoto T (2017) Elevation of pro-inflammatory cytokine levels following anti-resorptive drug treatment is required for osteonecrosis development in infectious osteomyelitis (in Eng). Sci Rep 7:46322. https:\/\/doi.org\/10.1038\/srep46322","journal-title":"Sci Rep"},{"key":"1608_CR18","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s00774-020-01174-2","volume":"39","author":"T Soma","year":"2021","unstructured":"Soma T, Iwasaki R, Sato Y, Kobayashi T, Nakamura S, Kaneko Y, Ito E, Okada H, Watanabe H, Miyamoto K, Matsumoto M, Nakamura M, Asoda S, Kawana H, Nakagawa T, Miyamoto T (2021) Tooth extraction in mice administered zoledronate increases inflammatory cytokine levels and promotes osteonecrosis of the jaw (in Eng). J Bone Miner Metab 39:372\u2013384. https:\/\/doi.org\/10.1007\/s00774-020-01174-2","journal-title":"J Bone Miner Metab"},{"key":"1608_CR19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41598-021-03966-6","volume":"12","author":"T Soma","year":"2022","unstructured":"Soma T, Iwasaki R, Sato Y, Kobayashi T, Ito E, Matsumoto T, Kimura A, Miyamoto K, Matsumoto M, Nakamura M, Morita M, Asoda S, Kawana H, Nakagawa T, Miyamoto T (2022) Osteonecrosis development by tooth extraction in zoledronate treated mice is inhibited by active vitamin D analogues, anti-inflammatory agents or antibiotics (in Eng). Sci Rep 12:19. https:\/\/doi.org\/10.1038\/s41598-021-03966-6","journal-title":"Sci Rep"},{"key":"1608_CR20","doi-asserted-by":"publisher","first-page":"1851112","DOI":"10.1080\/20002297.2020.1851112","volume":"13","author":"Q Li","year":"2021","unstructured":"Li Q, Pu Y, Lu H, Zhao N, Wang Y, Guo Y, Guo C (2021) Porphyromonas, Treponema, and Mogibacterium promote IL8\/IFN\u03b3\/TNF\u03b1-based pro-inflammation in patients with medication-related osteonecrosis of the jaw. J Oral Microbiol 13:1851112. https:\/\/doi.org\/10.1080\/20002297.2020.1851112","journal-title":"J Oral Microbiol"},{"key":"1608_CR21","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s11657-021-01019-z","volume":"16","author":"H Hagino","year":"2021","unstructured":"Hagino H, Jackson M, Gitlin M, Wessler Z (2021) Estimating the future clinical and economic benefits of improving osteoporosis diagnosis and treatment among women in Japan: a simulation projection model from 2020 to 2040. Arch Osteoporos 16:156. https:\/\/doi.org\/10.1007\/s11657-021-01019-z","journal-title":"Arch Osteoporos"},{"key":"1608_CR22","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1007\/s00198-022-06479-8","volume":"33","author":"MS LeBoff","year":"2022","unstructured":"LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, Siris ES (2022) Correction to: The clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int 33:2243\u20132343. https:\/\/doi.org\/10.1007\/s00198-022-06479-8","journal-title":"Osteoporos Int"},{"key":"1608_CR23","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0169-409X(00)00061-2","volume":"42","author":"A Ezra","year":"2000","unstructured":"Ezra A, Golomb G (2000) Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv Drug Deliv Rev 42:175\u2013195. https:\/\/doi.org\/10.1016\/S0169-409X(00)00061-2","journal-title":"Adv Drug Deliv Rev"},{"key":"1608_CR24","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.bone.2006.09.023","volume":"40","author":"M Asagiri","year":"2007","unstructured":"Asagiri M, Takayanagi H (2007) The molecular understanding of osteoclast differentiation. Bone 40:251\u2013264. https:\/\/doi.org\/10.1016\/j.bone.2006.09.023","journal-title":"Bone"},{"key":"1608_CR25","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1210\/endo-123-5-2600","volume":"123","author":"N Takahashi","year":"1988","unstructured":"Takahashi N, Akatsu T, Udagawa N, Sasaki T, Yamaguchi A, Moseley JM, Martin TJ, Suda T (1988) Osteoblastic cells are involved in osteoclast formation. Endocrinology 123:2600\u20132602. https:\/\/doi.org\/10.1210\/endo-123-5-2600","journal-title":"Endocrinology"},{"key":"1608_CR26","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","volume":"93","author":"DL Lacey","year":"1998","unstructured":"Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR et al (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165\u2013176. https:\/\/doi.org\/10.1016\/S0092-8674(00)81569-X","journal-title":"Cell"},{"key":"1608_CR27","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.3390\/jcm10132988","volume":"10","author":"H-W Kim","year":"2021","unstructured":"Kim H-W, Lee M-W, Lee J-H, Kim M-Y (2021) Comparison of the effect of oral versus intravenous bisphosphonate administration on osteoclastogenesis in advanced-stage medication-related osteonecrosis of the jaw patients. J Clin Med 10:2988","journal-title":"J Clin Med"},{"key":"1608_CR28","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40902-021-00310-w","volume":"43","author":"S-H Lee","year":"2021","unstructured":"Lee S-H, Choi S-Y, Bae M-S, Kwon T-G (2021) Characteristics of patients with osteonecrosis of the jaw with oral versus intravenous bisphosphonate treatment. Maxillofac Plastic Reconstr Surg 43:24. https:\/\/doi.org\/10.1186\/s40902-021-00310-w","journal-title":"Maxillofac Plastic Reconstr Surg"},{"key":"1608_CR29","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1196\/annals.1346.041","volume":"1068","author":"RG Russell","year":"2006","unstructured":"Russell RG (2006) Bisphosphonates: from bench to bedside (in Eng). Ann N Y Acad Sci 1068:367\u2013401. https:\/\/doi.org\/10.1196\/annals.1346.041","journal-title":"Ann N Y Acad Sci"},{"key":"1608_CR30","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S0022-3565(24)38786-5","volume":"296","author":"JE Dunford","year":"2001","unstructured":"Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ (2001) Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296:235\u2013242","journal-title":"J Pharmacol Exp Ther"},{"key":"1608_CR31","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","volume":"333","author":"UA Liberman","year":"1995","unstructured":"Liberman UA, Weiss SR, Br\u00f6ll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW, Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora AC, Lombardi A, Shah RV, Hirsch LJ, Karpf DB (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437\u20131444. https:\/\/doi.org\/10.1056\/NEJM199511303332201","journal-title":"N Engl J Med"},{"key":"1608_CR32","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S0002-9343(97)00249-0","volume":"103","author":"D Thi\u00e9baud","year":"1997","unstructured":"Thi\u00e9baud D, Burckhardt P, Kriegbaum H, Huss H, Mulder H, Juttmann JR, Sch\u00f6ter KH (1997) Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 103:298\u2013307. https:\/\/doi.org\/10.1016\/S0002-9343(97)00249-0","journal-title":"Am J Med"},{"key":"1608_CR33","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.bone.2005.05.004","volume":"37","author":"D Felsenberg","year":"2005","unstructured":"Felsenberg D, Miller P, Armbrecht G, Wilson K, Schimmer RC, Papapoulos SE (2005) Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis. Bone 37:651\u2013654. https:\/\/doi.org\/10.1016\/j.bone.2005.05.004","journal-title":"Bone"},{"key":"1608_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001155.pub2","author":"GA Wells","year":"2008","unstructured":"Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Welch V, Coyle D, Tugwell P (2008) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD001155.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"1608_CR35","first-page":"488","volume":"35","author":"JA Eisman","year":"2008","unstructured":"Eisman JA, Civitelli R, Adami S, Czerwi\u0144ski E, Recknor C, Prince RL, Reginster J-Y, Zaidi M, Felsenberg D, Hughes C, Mairon N, Masanauskaite D, Reid DM, Delmas PD, Recker RR (2008) Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol 35:488\u2013497","journal-title":"J Rheumatol"},{"key":"1608_CR36","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1056\/NEJMoa011807","volume":"346","author":"IR Reid","year":"2002","unstructured":"Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P et al (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653\u2013661. https:\/\/doi.org\/10.1056\/NEJMoa011807","journal-title":"N Engl J Med"},{"key":"1608_CR37","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, Reid IR, Boonen S et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822. https:\/\/doi.org\/10.1056\/NEJMoa067312","journal-title":"N Engl J Med"},{"key":"1608_CR38","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/odi.14003","volume":"29","author":"LHI Martins","year":"2023","unstructured":"Martins LHI, Ferreira DC, Silva MT, Motta RHL, Franquez RT, Bergamaschi CdC (2023) Frequency of osteonecrosis in bisphosphonate users submitted to dental procedures: a systematic review. Oral Dis 29:75\u201399. https:\/\/doi.org\/10.1111\/odi.14003","journal-title":"Oral Dis"},{"key":"1608_CR39","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s10549-009-0432-z","volume":"116","author":"D Mauri","year":"2009","unstructured":"Mauri D, Valachis A, Polyzos IP, Polyzos NP, Kamposioras K, Pesce LL (2009) Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a metanalysis. Breast Cancer Res Treat 116:433\u2013439. https:\/\/doi.org\/10.1007\/s10549-009-0432-z","journal-title":"Breast Cancer Res Treat"},{"key":"1608_CR40","doi-asserted-by":"publisher","first-page":"105599","DOI":"10.1016\/j.jbspin.2023.105599","volume":"90","author":"C Amigues","year":"2023","unstructured":"Amigues C, Fresse A, Roux CH, Gauthier S, Vieillard M-H, Drici M-D, Breuil V (2023) Zoledronate and osteonecrosis of the jaw in osteoporosis: incidence and risk factors. Analysis of the French Pharmacovigilance Database. Joint Bone Spine 90:105599. https:\/\/doi.org\/10.1016\/j.jbspin.2023.105599","journal-title":"Joint Bone Spine"},{"key":"1608_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-025600","volume":"9","author":"E Veszelyn\u00e9 Kot\u00e1n","year":"2019","unstructured":"Veszelyn\u00e9 Kot\u00e1n E, Bartha-Lieb T, Parisek Z, Mesk\u00f3 A, Vaszilk\u00f3 M, Hank\u00f3 B (2019) Database analysis of the risk factors of bisphosphonate-related osteonecrosis of the jaw in Hungarian patients. BMJ Open 9:e025600. https:\/\/doi.org\/10.1136\/bmjopen-2018-025600","journal-title":"BMJ Open"},{"key":"1608_CR42","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1200\/jco.2003.04.105","volume":"21","author":"LS Rosen","year":"2003","unstructured":"Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, Souza Pd, Zheng M, Urbanowitz G, Reitsma D, Seaman JJ (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a Phase III, double-blind, randomized trial\u2014the zoledronic acid lung cancer and other solid tumors Study Group. J Clin Oncol 21:3150\u20133157. https:\/\/doi.org\/10.1200\/jco.2003.04.105","journal-title":"J Clin Oncol"},{"key":"1608_CR43","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1200\/jco.2005.05.116","volume":"23","author":"N Kohno","year":"2005","unstructured":"Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, Watanabe T, Goessl C, Ohashi Y, Takashima S (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23:3314\u20133321. https:\/\/doi.org\/10.1200\/jco.2005.05.116","journal-title":"J Clin Oncol"},{"key":"1608_CR44","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the Phase 3 Randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5:513\u2013523. https:\/\/doi.org\/10.1016\/S2213-8587(17)30138-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1608_CR45","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","volume":"379","author":"MR Smith","year":"2012","unstructured":"Smith MR, Saad F, Coleman R, Shore N, Fizazi K et al (2012) Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a Phase 3, Randomised, placebo-controlled trial. The Lancet 379:39\u201346. https:\/\/doi.org\/10.1016\/S0140-6736(11)61226-9","journal-title":"The Lancet"},{"key":"1608_CR46","doi-asserted-by":"publisher","unstructured":"Diz P, L\u00f3pez-Cedr\u00fan JL, Arenaz J, Scully C (2012) Denosumab-related osteonecrosis of the jaw. J Am Dental Assoc 143:981\u2013984 https:\/\/doi.org\/10.14219\/jada.archive.2012.0323","DOI":"10.14219\/jada.archive.2012.0323"},{"key":"1608_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.116184","volume":"153","author":"JI Aguirre","year":"2021","unstructured":"Aguirre JI, Castillo EJ, Kimmel DB (2021) Preclinical models of medication-related osteonecrosis of the jaw (MRONJ) (in Eng). Bone 153:116184. https:\/\/doi.org\/10.1016\/j.bone.2021.116184","journal-title":"Bone"},{"key":"1608_CR48","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.ijom.2014.08.011","volume":"44","author":"O Sakaguchi","year":"2015","unstructured":"Sakaguchi O, Kokuryo S, Tsurushima H, Tanaka J, Habu M, Uehara M, Nishihara T, Tominaga K (2015) Lipopolysaccharide aggravates bisphosphonate-induced osteonecrosis in rats. Int J Oral Maxillofac Surg 44:528\u2013534. https:\/\/doi.org\/10.1016\/j.ijom.2014.08.011","journal-title":"Int J Oral Maxillofac Surg"},{"key":"1608_CR49","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1124\/jpet.102.035295","volume":"302","author":"J Wood","year":"2002","unstructured":"Wood J, Bonjean K, Ruetz S, Bellahc\u00e8ne A, Devy L, Foidart JM, Castronovo V, Green JR (2002) Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302:1055\u20131061. https:\/\/doi.org\/10.1124\/jpet.102.035295","journal-title":"J Pharmacol Exp Ther"},{"key":"1608_CR50","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1172\/JCI200422087","volume":"114","author":"E Giraudo","year":"2004","unstructured":"Giraudo E, Inoue M, Hanahan D (2004) An amino-bisphosphonate targets MMP-9 - Expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Investig 114:623\u2013633. https:\/\/doi.org\/10.1172\/JCI200422087","journal-title":"J Clin Investig"},{"key":"1608_CR51","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.semcancer.2019.12.001","volume":"68","author":"NM La-Beck","year":"2021","unstructured":"La-Beck NM, Liu X, Shmeeda H, Shudde C, Gabizon AA (2021) Repurposing amino-bisphosphonates by liposome formulation for a new role in cancer treatment. Semin Cancer Biol 68:175\u2013185. https:\/\/doi.org\/10.1016\/j.semcancer.2019.12.001","journal-title":"Semin Cancer Biol"},{"key":"1608_CR52","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/BF02556671","volume":"41","author":"S Adami","year":"1987","unstructured":"Adami S, Bhalla AK, Dorizzi R, Montesanti F, Rosini S, Salvagno G, Lo Cascio V (1987) The acute-phase response after bisphosphonate administration. Calcif Tissue Int 41:326\u2013331. https:\/\/doi.org\/10.1007\/BF02556671","journal-title":"Calcif Tissue Int"},{"key":"1608_CR53","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1007\/s00198-017-3992-5","volume":"28","author":"AW Popp","year":"2017","unstructured":"Popp AW, Senn R, Curkovic I, Senn C, Buffat H, Popp PF, Lippuner K (2017) Factors associated with acute-phase response of bisphosphonate-na\u00efve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate. Osteoporos Int 28:1995\u20132002. https:\/\/doi.org\/10.1007\/s00198-017-3992-5","journal-title":"Osteoporos Int"},{"key":"1608_CR54","first-page":"21","volume":"4","author":"C Fondi","year":"2007","unstructured":"Fondi C, Franchi A (2007) Definition of bone necrosis by the pathologist (in Eng). Clin Cases Miner Bone Metab 4:21\u201326","journal-title":"Clin Cases Miner Bone Metab"},{"key":"1608_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.105512","volume":"300","author":"T Arima","year":"2024","unstructured":"Arima T, Sugimoto K, Taniwaki T, Maeda K, Shibata Y et al (2024) Cartilage tissues regulate systemic aging via ectonucleotide pyrophosphatase\/phosphodiesterase 1 in mice. J Biol Chem 300:105512. https:\/\/doi.org\/10.1016\/j.jbc.2023.105512","journal-title":"J Biol Chem"},{"key":"1608_CR56","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.bbrc.2020.11.122","volume":"534","author":"E Ito","year":"2021","unstructured":"Ito E, Sato Y, Kobayashi T, Nakamura S, Kaneko Y, Soma T, Matsumoto T, Kimura A, Miyamoto K, Matsumoto H, Matsumoto M, Nakamura M, Sato K, Miyamoto T (2021) Food restriction reduces cortical bone mass and serum insulin-like growth factor-1 levels and promotes uterine atrophy in mice. Biochem Biophys Res Commun 534:165\u2013171. https:\/\/doi.org\/10.1016\/j.bbrc.2020.11.122","journal-title":"Biochem Biophys Res Commun"},{"key":"1608_CR57","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 48:452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-025-01608-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00774-025-01608-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-025-01608-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T16:00:22Z","timestamp":1757174422000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00774-025-01608-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1608"],"URL":"https:\/\/doi.org\/10.1007\/s00774-025-01608-9","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,28]]},"assertion":[{"value":"13 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest with the contents of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"C57BL\/6\u00a0J wild-type mice used in the study were purchased from SLC (Shizuoka, Japan). All animals were maintained under specific pathogen-free conditions, and were housed under a 12-h dark\u2013light cycle (light from 07:00 to 19:00) at 22\u2009\u00b1\u20091\u00a0\u00b0C with ad libitum food and water. The Animal Care and Use Committee of Kumamoto University approved the protocols for animal experiments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}